Medication Monitor



Generic Name (Trade Name—Company)
Notes
July 8, 2011

Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed

(Boostrix—GlaxoSmithKline)
Tdap booster for older patients

Uses:

Prevention of tetanus, diphtheria, and pertussis in patients 65 years of age and older

FDA announced that Boostrix, given as a single-dose booster shot, has been approved for this additional indication. This is the only vaccine approved to prevent all three diseases in older patients. Boostrix was previously approved for patients 10 through 64 years of age. Data from approximately 1,300 patients showed that antibody responses to pertussis, tetanus, and diphtheria in patients ages 65 and older were comparable with those observed with previous vaccines. Headache, fatigue, and pain at the injection site were the most common adverse events observed in this patient population.